事实上,美国FDA尚未正式批准任何一种精神药物 risk of persistent pulmonary hypertension in the newborn:
可以用于妊娠期,因为没有任何一种精神药物对胎儿的 population based cohort study from the five Nordic coun‐
发育是绝对安全的。妊娠期使用抗抑郁药的情况分析 tries[J]. BMJ,2012,344:d8012.
显示,在 2004-2010 年期间,英国和丹麦 2 个国家西酞 [ 9 ] NIJENHUIS C M,TER HORST P G,VAN REIN N,et al.
Disturbed development of the enteric nervous system after
普兰和舍曲林的使用量稳步增加,帕罗西汀的使用量略
in utero exposure of selective serotonin re-uptake inhibi‐
有下降;但帕罗西汀在意大利和荷兰却很受欢迎 。
tors and tricyclic antidepressants. Part 2:testing the hy‐
2005-2014 年美国使用 SSRI 的数据分析显示,大约
potheses[J]. Br J Clin Pharmacol,2012,73(1):126-134.
4.3% 的美国孕妇使用过 SSRI,最常见的药物是舍曲林
[10] JIMENEZ-SOLEM E,ANDERSEN J T,PETERSEN M,
(49.0%),但帕罗西汀的使用率在降低;艾司西酞普兰和 et al. SSRI use during pregnancy and risk of stillbirth and
舍曲林在高收入人群中使用更多 。总体而言,相关指
neonatal mortality[J]. Am J Psychiatry,2013,170(3):
南建议在妊娠早期避免使用帕罗西汀,使用帕罗西汀可 299-304.
能会增加新生儿先天性心血管畸形的风险,围产期首选 [11] PALMSTEN K,HERNÁNDEZ-DÍAZ S,HUYBRECHTS
药物包括舍曲林和西酞普兰 。本研究也表明,妊娠中 K F,et al. Use of antidepressants near delivery and risk of
晚期使用帕罗西汀与使用 SSRI 相比安全性相当,但需 postpartum hemorrhage:cohort study of low income
警惕新生儿肺动脉高压的发生。因此,在妊娠期应尽量 women in the United States[J]. BMJ,2013,347:f4877.
选择其他安全性更高的抗抑郁药。 [12] PALMSTEN K,HUYBRECHTS K F,MICHELS K B,et
由于本研究纳入的人群为妊娠期妇女,研究对象较 al. Antidepressant use and risk for preeclampsia[J]. Epide‐
为特殊,纳入的文献数量有限,这可能会对研究结果产 miology,2013,24(5):682-691.
[13] BÉRARD A,BOUKHRIS T,SHEEHY O. Selective sero‐
生一定的影响;另外,孕妇不良妊娠结局以及新生儿不
tonin reuptake inhibitors and autism:additional data on
良结局影响因素较多,这可能也会影响研究结果。为进
the Quebec Pregnancy/Birth Cohort[J]. Am J Obstet Gyne‐
一步明确妊娠中晚期使用帕罗西汀对母婴结局的影响,
col,2016,215(6):803-805.
仍需继续收集相关研究数据。
[14] 王年生,李荣琴 . SSRIs 的戒断症状[J]. 四川精神卫生,
参考文献 1998,11(1):69-70.
[ 1 ] 张爱英,赵让.妊娠期抑郁症患者用药安全[J].滨州医学 [15] SANZ E J,DE-LAS-CUEVAS C,KIURU A,et al. Selec‐
院学报,2020,43(5):399-400. tive serotonin reuptake inhibitors in pregnant women and
[ 2 ] ANDRADE S E,RAEBEL M A,BROWN J,et al. Use of neonatal withdrawal syndrome:a database analysis[J].
antidepressant medications during pregnancy:a multisite Lancet,2005,365(9458):482-487.
study[J]. Am J Obstet Gynecol,2008,198(2):194.e1-194.e5. [16] MASARWA R,BAR-OZ B,GORELIK E,et al. Prenatal
[ 3 ] ALWAN S,REEFHUIS J,RASMUSSEN S A,et al. Pat‐ exposure to selective serotonin reuptake inhibitors and se‐
terns of antidepressant medication use among pregnant rotonin norepinephrine reuptake inhibitors and risk for per‐
women in a United States population[J]. J Clin Pharma‐ sistent pulmonary hypertension of the newborn:a syste-
col,2011,51(2):264-270. matic review,meta-analysis,and network meta-analysis
[ 4 ] WILLIAMS M,WOOLTORTON E. Paroxetine (paxil) [J]. Am J Obstet Gynecol,2019,220(1):57.e1-57.e13.
and congenital malformations[J]. J De L’association Med [17] CHARLTON R A,JORDAN S,PIERINI A,et al. Selec‐
Can,2005,173(11):1320-1321. tive serotonin reuptake inhibitor prescribing before,
[ 5 ] COSTEI A M,KOZER E,HO T,et al. Perinatal outcome during and after pregnancy:a population-based study in
following third trimester exposure to paroxetine[J]. Arch six European regions[J]. BJOG,2015,122(7):1010-1020.
Pediatr Adolesc Med,2002,156(11):1129-1132. [18] PETERSEN J M,ESPOSITO D B,WERLER M M. Selec‐
[ 6 ] KÄLLÉN B. Neonate characteristics after maternal use of tive serotonin reuptake inhibitor use patterns among com‐
antidepressants in late pregnancy[J]. Arch Pediatr Adolesc mercially insured US pregnancies:2005-2014[J]. Arch
Med,2004,158(4):312-316. Womens Ment Health,2021,24(1):155-164.
[ 7 ] COLVIN L,SLACK-SMITH L,STANLEY F J,et al. Di- [19] MOLENAAR N M,KAMPERMAN A M,BOYCE P,et
spensing patterns and pregnancy outcomes for women al. Guidelines on treatment of perinatal depression with
dispensed selective serotonin reuptake inhibitors in preg‐ antidepressants:an international review[J]. Aust N Z J
nancy[J]. Birth Defects Res A Clin Mol Teratol,2011,91 Psychiatry,2018,52(4):320-327.
(3):142-152. (收稿日期:2022-07-28 修回日期:2022-12-26)
[ 8 ] KIELER H,ARTAMA M,ENGELAND A,et al. Selec‐ (编辑:刘明伟)
tive serotonin reuptake inhibitors during pregnancy and